An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
NCT01833039 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS
Last updated 2025-02-03
Summary
The purpose of this study is to provide patients who have relapsed or refractory Mantle Cell Lymphoma (MCL) with early access to an investigational medication called ibrutinib (PCI-32765) and to collect safety information about the drug.
Conditions
- Relapsed or Refractory Mantle Cell Lymphoma
Interventions
- DRUG
-
Ibrutinib
Sponsors & Collaborators
-
Pharmacyclics LLC.
collaborator INDUSTRY -
Janssen Biotech, Inc.
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
- Brazil
- Puerto Rico
Study Locations
More Related Trials
-
A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy
NCT01599949 ·Status: COMPLETED ·Phase: PHASE2
-
Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma
NCT02242097 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
NCT05564052 ·Status: COMPLETED ·Phase: PHASE2
-
Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL
NCT02419560 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL
NCT04876092 ·Status: COMPLETED ·Phase: PHASE1
-
Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)
NCT02315326 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
NCT01855750 ·Status: COMPLETED ·Phase: PHASE3
-
A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas
NCT02401048 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma
NCT01980654 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
NCT05431179 ·Status: WITHDRAWN ·Phase: PHASE3
-
Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL
NCT02682641 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma
NCT01980628 ·Status: COMPLETED ·Phase: PHASE2
-
Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)
NCT03581942 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma
NCT01880567 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)
NCT03703167 ·Status: COMPLETED ·Phase: PHASE1
-
Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT02077166 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor
NCT03235544 ·Status: COMPLETED ·Phase: PHASE2
-
Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma
NCT03282396 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma
NCT02756247 ·Status: COMPLETED ·Phase: PHASE1
-
A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients
NCT02558816 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL
NCT02747732 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse
NCT03229382 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma
NCT01974440 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma
NCT02542514 ·Status: COMPLETED ·Phase: PHASE2
-
Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma
NCT02689869 ·Status: UNKNOWN ·Phase: PHASE2